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ABSTRACT 
Objective: Knowledge of doctors and their understanding of generic drugs could facilitate in recognizing potential barriers to larger generic 
medicine prescriptions. Hence, the primary objective of this study was focused to explore knowledge, attitude, and practice (KAP) of doctors toward 
generic medicines. 
Methods: It is a cross-sectional questionnaire-based study. The study participants are the doctors working in the hospital during the study period 
(2016–2017). The questionnaire designed for this study comprised of thirty-five questions related to the knowledge, attitude, and practice (KAP) of 
generic medicine and about demographic details of the participants.  
Results: A total of 86 questionnaires were distributed among the health care professionals and the response rate is 37%. The majority of doctors 
who participated in this survey perceived that generic medicine is effective, safe and need to have the same active component, dose and 
bioequivalent as the brand name medicines. Most of the doctors (72%) were of the view that generic drugs were manufactured in poor quality than 
branded medicines. More than three-quarters of doctors (78%) prescribed generic drugs.  
Conclusion: Majority of the participants had an honest angle about the efficaciousness and safety of generic and though they sometimes prescribe 
generic medicine, however a high range of doctors (72%) were of the opinion that generic was of poorer quality than brand medicine. To have a 
better understanding of the generic drug, the doctor must be well informed about the generics during their academic career resulting in savings to 
healthcare budgets.  
Keywords: Generic drugs, Questionnaires, Knowledge, Attitude, Practice 
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INTRODUCTION 
Healthcare expenditure is increasing steadily worldwide and 
prescription drug spending is increasing and out-of-pocket expenses are 
80% of total health-care expenditures [1]. In developing countries, out-
of-pocket payment is as high as 80% of healthcare spending and a 
similar scenario are observed in the Indian healthcare system. Between 
1986 and 2004, the average real expenditure per hospital admission 
increased three times in both government and private hospitals. Most 
healthcare expenses are paid out of pocket by patients and their families, 
rather than through medical insurance. This has led over 35% of Indian 
households to incur Catastrophic Health Expenditure (CHE) and hence 
poses a burden of affordability of medicine [2, 3]. Generic medicine 
utilization is often encouraged to curb the cost of medicine as the generic 
product are usually lower in price than innovator brands leading to 
substantial savings of health care expenditure [4-6]. 
Although the generic medicines are bioequivalent of their innovator 
products and are produced according to good manufacturing 
practices (GMP), physicians are apprehensive regarding the quality 
and reliability of generic drugs as compared to their brand innovator 
and resist prescribing them [7, 8]. 
Therefore, understanding doctor's perceptions and an 
understanding of generic medicines may help in recognizing 
possible barriers to greater generic medicine usage. Hence, the 
primary objective of this study was focused to explore knowledge, 
attitude, and practice (KAP) of doctors toward generic medicines. 
MATERIALS AND METHODS 
Methods 
The study was conducted in a tertiary-care teaching hospital in 
North-East India after obtaining due permission from the 
institutional ethics committee (NEIGR/IEC/2015/0039). 
Study design 
It is a cross-sectional questionnaire-based study. The study 
participants were all the doctors working in the hospital during the 
study period. The questionnaire designed for this study was 
comprised of 35 questions related to the knowledge, attitude, and 
practice (KAP) of generic medicine and about demographic details of 
the participants. The questionnaire consisted of four sections. The first 
section focused on doctors' demographic data. The second section was 
a set of twelve statements and aimed to assess their knowledge about 
generic medicines. The third section comprised fourteen statements 
investigating doctors' attitude on issues about generic medicine 
utilization in the hospital. The fourth section consisted of nine 
questions related to the practice of generic medicine. 
Data collection 
All doctors from the study hospital were informed about the study 
utilizing an invitation letter by researchers one week before the 
study, and a reminder card was sent one day before the session. On 
the day of the data collection, structured and pre-validated 
questionnaires were distributed to the doctors who gave consent for 
participating in the study. For pre-validation, questions were 
subjected to cognitive testing with five physicians who were shown 
the questions and allowed to provide responses and their feedback 
regarding their understanding of the questions. Accordingly, 
necessary amendments were made to the questions before the main 
study. The responses of these physicians were included in the 
analysis. The study participants had to fill up the questionnaire 
anonymously within 60 min and return the same to the researcher. 
Statistical analyses 
Descriptive statistics, including frequency calculations, percentages 
and means, were used to analyze demographics of the participants 
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and respective answers on different categories of the 
questionnaires. 
RESULTS 
Response rate-A total of 86 questionnaires was distributed among 
the health care professionals and 32 responded (response rate 
37%). 
Demographic characteristics-The demographic details of the 
participants have been summarized in table 1. 
Knowledge 
Seventy-eight percent (78%) doctors agreed that generic medicine is 
bioequivalent to a brand name medicine. Seventy-two percent 
(72%) and seventy-five percent (75%) doctors were aware that 
generic medicines are the same dosage form and contain the same 
dose as the brand name medicines, respectively. Eighty-four (84%) 
doctors did not agree that generics are less effective and produce 
more side effects than brand name medicines. Sixty-six percent 
(66%) doctors disagreed that brand name drugs meet higher safety 
standard, but seventy-two percent (72%) doctors were not satisfied 
with the quality of generic drugs. Seventy-two percent (72%) 
doctors were unaware that generic drugs can be only marketed after 
the expiry date of the patent of original drugs. Among study 
participants, fifty (50%) doctors knew that generic drug 
manufacturers need not repeat the preclinical and clinical studied of 
original drugs but eighty-one percent (81%) doctors were aware 
that generic drug manufacturers need to conduct bioequivalence 
studies to show the equivalence of generic and original drugs. 
Among the participants, fifty-six (56%) doctors told that they were 
aware regarding the JanAushadhi scheme and eighty-four (84%) 
doctors were aware of the Indian Medical Council (IMC) act to 
prescribe drugs with generic names.  
Knowledge related questionnaires and their responses are 
summarized in table 2. 
 
Table 1: Demographic details of the participants (n = 32) 
Factors   Frequency (%)  
Gender Male 56 
 Female 44 
Age(years) 20-30 66 
 30-40 34 
 Mean 31.32+/-04.22 
Qualification MBBS 66  
 MD 28 
 DM 06 
 
Table 2: Knowledge-related questions and frequency (%) of responses 
S. No. Questions Yes (%) No (%) 
1 A generic medicine is bioequivalent to a brand name medicine 78 13 
2 A generic medicine must be in the same dosage form as the brand name medicine 72 28 
3 A generic medicine must contain the same dose as the brand name medicines 75 22 
4 Generic medicines are less effective compared to brand name medicines 13 84 
5 Generic medicines produce more side effects compared to brand name medicines 13 84 
6 Brand name medicines meet higher safety standards than generic medicines 31 66 
7 Generic drugs can be only marketed after the expiry date of the patent of original drug 19 72 
8 Generic drug manufacturer need to repeat the preclinical and clinical studies required for original drug 50 44 
9 Generic drug manufacturers need to conduct bioequivalence studies to demonstrate equivalence 
between the generic medicine and the original drug 
81 13 
10 Are you aware of the scheme of Government of India called Jan Aushadhi? 44 56 
11 Are you aware about the Indian Medical Council (IMC) Act to prescribe drugs with Generic names 84 16 
12 Are you satisfied with the quality control measure of generic medicines by the Regulatory authority 25 72 
 
Attitude 
Majority of doctors (69%) were of the view that generic drugs were 
as safe as branded drugs and eighty-four percent (84%) doctors felt 
that there is a huge price difference so that they prescribe cheaper 
generic substitutes. Seventy-five percent (75%) doctors did not 
agree that generic drugs cost less because they are inferior to brand 
name drugs and sixty-six percent (66%) doctors agreed that both 
generic and branded drugs have the same quality in general. 
Another sixty-two percent (62%) doctors disagreed that brand 
names are easy to remember, eighty-seven (87%) doctors felt 
that both prescriber and pharmacist if work together, there is 
more use of generic drugs in society and ninety-four 
percent(94%) participants felt that there should be a standard 
guideline to prescribe generic medicines. Only 91% of doctors 
mentioned they give enough information to the patients about 
generic medicines and their price differences. It is observed that 
72% of participants felt that they need more information related 
to safety and efficacy of generic medicines, and 38% of doctors 
felt that advertisement by the drug companies will influence 
their future prescribing pattern. 
Majority of doctors (91%) agreed that there should be a training 
program to increase the awareness regarding generic drug use 
among doctors and patients and there should be a general medicine 
store in every hospital. Only 38% of doctors are satisfied with the 
marketing permission process granted to generic medicines and not 
satisfied with the quality control measures of it. 
Attitude related questionnaires and their responses are summarized 
in table 3. 
Practice 
Majority of doctors (78%) prescribed generic drugs to their patients 
and 63% of them prescribed as much as 1 to 3 generics per 
prescription. Doctors prescribe generic medicine for their patients 
and themselves in 69% and 63% cases, respectively. As many as 
47% of doctors discussed with their patients regarding generic 
drugs and 84% of them felt that the patient’s socioeconomic 
condition influenced their prescription, as shown in table 4. 
Seventeen (53%) out of the total respondent of doctors did not think 
that switching all patients from branded drugs to generic may 
change the outcome of the therapy, but only 38% of participants 
thought switching brand name drugs with narrow therapeutic range 
to generic may change the outcome of the patient. Most of the 
doctors (38%) got information regarding the availability of generic 
drugs from the Internet, followed by Journal (12.5%), Drug 
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compendium (12.5%) and Medical representatives (12.5%) etc. 
Majority of doctors (81%) never received any free sample of generic 
medicines but received (81%) free samples of branded drugs.66% 
participants stated that representatives of generic drug 
manufacturers never visited them but 59% of doctors were visited 
weekly by Representative of brand name drugs manufacturers. 
  
Table 3: Attitude-related questions and frequency (%) of responses 
S. No. Questions Disagree (%) Neutral (%) Agree (%) 
1 Generics are as safe as branded drugs 13 19 69 
2 The price difference between generic and brand name drugs is often so great that I 
feel I must prescribe generic substitutes 
0 16 84 
3 Generic drugs cost less because they are inferior to Brand name drugs 75 6 16 
4 Generic medicines are generally of the same quality as brand-name drugs  19 16  66 
5 It is easier to remember brand names, rather than generic drug names 62 16 22 
6 Quality use of generic medicines among patients can be achieved if both 
prescribers and pharmacist work together 
0 13 87 
7 We need a standard guideline to prescribe generic medicines 0 6 94 
8 Patient should be given enough information about generic medicines in order to 
make sure they really understand about the medicines they take 
0 9 91 
9 Advertisement by the drug companies will influence my future prescribing pattern 22 38 38 
10 Need more information on the issues pertaining to the safety and efficacy of 
generic medicines 
0 25 72 
11 There should be a training program to increase awareness regarding generic 
drugs among doctors and patients  
0 9 91 
12 There should be a generic medicine store in every hospital  0 9 91 
13 Satisfied with the marketing permission process granted to generic medicine 34 28 38 
14 Satisfied with the quality control measures of generic medicines 38 28 31 
 
Table 4: Practice-related questions and frequency (%) of responses 
S. No. Questions Yes (%) No (%) 
1 Do you prescribe generic drugs to your patients? 78 19 
2 Have you ever taken Generic Medicine? 63 34 
3 Have you ever prescribed generic medicine to your family members? 69 28 
4 Have you ever talked to your patient regarding Generic drugs? 47 50 
5 Do you think that switching all patients from a brand name to generics may change the outcome 
of the therapy? 
41 53 
6 Do you think switching brand name drugs with narrow therapeutic range to generic may change 
the outcome of the therapy of patient? 
38 56 
7 Does the socioeconomic condition of your patient influence your prescription? 84 09 
8 Have you ever received free samples of Generic drugs? 16 81 
9 Have you ever received free samples of Brand name drugs? 81 16 
 
DISCUSSION 
The response rate achieved in this study, too, was 37%, which is 
quite similar to the earlier study by Kumar et al. [9]. It is more 
challenging to obtain high response rate, especially from doctors 
practicing not only in private healthcare sectors but also in 
Government hospitals. Moreover, Kellerman and Herold reported 
that nonresponse bias may be of less concern to physicians because 
they are considered to be consistent in opinion and view regarding 
knowledge, attitude and practice [10, 11]. 
The majority of doctors who participated in this survey perceived 
that generic medicine is effective, safe and needs to have the same 
active component, dose and bioequivalent as the brand name 
medicines. It is quite similar to the earlier study by Jamshed et al. as 
stated correct knowledge about generic medicine being a “Copy of 
the brand name medicine” [11, 12]. 
In the present study, the majority of doctors (81%) were aware of 
bioequivalence studies, which are required by generic drug 
manufacturers during generic product approval system. Our finding 
is better than the finding reported by Chua et al. and Hassali et al. 
where 4.6% and 33.3% doctors respectively were aware of the 
bioequivalence standards for generic products [12, 13]. 
Most of the respondents in our study were unaware about some 
regulatory requirements (like generic marketed after the expiry of 
the patent of the originator or no need to repeat preclinical and 
clinical study for the generic product) imposed on generic drugs as 
stated in earlier studies [14]. A large number of doctors (72%) were 
of the view that generic was manufactured to the poorer quality 
than brand name medicines. According to the present analysis, close 
to three-quarters of the participants had a good attitude about the 
efficacy and safety of generic medicines, and the majority of doctors 
actively prescribe generic medicines similar to the earlier study [15, 
16]. Moreover, various studies have reported that generic medicines 
neither differ substantially from their innovator counterparts nor 
related to poor efficacy or safety and even favored the use of generic 
drugs in treating various diseases [17, 18]. 
In our survey, the majority of doctors were aware of the huge price 
difference between generic and brand name products, and they give 
enough information to the patient about generic medicines with 
their price differences. They also prescribe cheaper generic 
substitutes, considering the patient socioeconomic condition. It was 
earlier reported that the cost of generic medicines is up to 91% less 
than that of the brand name drugs [19-22]. 
The rising health care expenses remain a serious concern for the 
health care system worldwide, especially in developing countries 
like India where availability and affordability of medicine are a 
major concern. To tackle this problem, the Indian Government 
started a project "Jan Ausadhi" to supply essential low priced 
generic medicine on-demand to Jan Ausadhi stores. Only half of the 
participants in our study were aware of regarding Jan Ausadhi 
Scheme. The expansion of the generic market should have a positive 
impact on patients ‘access to cheaper drugs [22-25]. 
Though most of the participating doctors received a free sample of 
branded drugs and half of the participants were visited weekly by 
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the representative of brand name medicine manufacturers in our 
study, but a few of doctors (38%) felt that advertisement by the drug 
company will influence their future prescribing pattern which is 
contradictory to earlier studies where they stated the presence of 
heavy and successful promotional activities from branded product 
industry may negatively influence generic prescribing [26-28]. 
More than three-quarters of doctors (78%) prescribed generic drugs 
and they (84%) were aware of the Indian Medical Council (IMC) Act 
to prescribe drugs in generic names in the present study. Our result 
is far better than the previous studies in Bahrain (10.2%), Belgium 
(2.8%), Malaysia (12.7%) and USA (2-22%) but is quite similar to 
the earlier studies in the UK (83%) and Thailand (73.9%) [29, 30]. 
This may be due to the introduction and encouraging generic 
prescribing at the early stage of medical school and the Indian 
Medical Council (IMC) Act to prescribe drugs in generic names. Even 
in Europe, several measures and interventions have been taken to 
enhance prescribing in generic medicines [30-32]. 
Although majority of the doctors surveyed had good knowledge and 
attitude about generic medicines and a meaningful proportion of 
doctors actively prescribed generic drugs, still more information 
about generic drugs are needed by them especially on quality to 
increase generic medicine prescription rates [33, 34]. Participating 
doctors also agreed that it was important to establish a greater 
collaboration between them and the pharmacists, in order to 
improve generic utilization among consumers. They also expressed 
the need for standard guidelines on generic substitution policy.  
LIMITATION 
A possible limitation of this study could be the small sample size, thus 
findings of this study can hardly be generalized. A further potential 
limitation may be the manner of participant selection as all doctors 
participating had a university affiliation and working in the tertiary 
medical teaching hospital. Other limitation may be such as the age of the 
participants as most of our participants are young fresh medical 
graduates (age range 20-40yrs and 2/3 doctors have less than 10 y of 
experience after their medical graduation). Lastly, we have only analyzed 
the doctor’s view, perception, knowledge, attitude, and practice about 
generic medicine prescribing. It would be appropriate also to know the 
opinion, belief, and level of understanding of pharmacists and patients 
about generic medicines and analysis of prescriptions. 
CONCLUSION 
Although majority of the doctors surveyed had good knowledge and 
attitude about generic medicines and a meaningful proportion of 
doctors actively prescribed generic drugs, still more information 
about generic drugs are needed by them especially on quality to 
increase generic medicine prescription rates. In order to have a 
better understanding of generic, the doctor must be well informed 
about the generic during their academic career resulting in savings 
to healthcare budgets. They also expressed the need for standard 
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